Nasdaq

MIT and Recursion Unveil Boltz-2: A Revolutionary Open-Source Biomolecular Co-Folding Model with Advanced Structure and Binding Affinity Prediction

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...
Nasdaq

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio SALT LAKE CITY, Nov. 09, 2023 ...
Yahoo Finance

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading ...
Yahoo Finance

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Globe and Mail

Nvidia Invested $50 million into This AI Drug Discovery Biotech

Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) leader Nvidia ...
Business Times

Nvidia-backed Recursion’s shares fall on mixed data for rare disorder drug

NVIDIA-BACKED Recursion Pharmaceuticals said on Tuesday (Sep 3) its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results for ...